Vol 54, No 4 (2020)
Research paper
Published online: 2020-06-08
Submitted: 2019-12-01
Accepted: 2020-03-13
Get Citation

Pentosidine, advanced glycation end product, in acute ischaemic stroke patients with and without atrial rhythm disturbances

Marta Leńska-Mieciek, Grażyna Korczak-Kowalska, Katarzyna Bocian, Urszula Fiszer
DOI: 10.5603/PJNNS.a2020.0042
·
Pubmed: 32510570
·
Neurol Neurochir Pol 2020;54(4):323-328.

paid access

Vol 54, No 4 (2020)
Research paper
Published online: 2020-06-08
Submitted: 2019-12-01
Accepted: 2020-03-13

Abstract

Atrial fibrillation (AF) and atherosclerotic disease are independent risk factors for acute ischaemic stroke (AIS). The optimal biological marker which could allow differentiation between AF and non-AF AIS patients is still not available.

Aim of the study. Aim of the present study was to investigate the role of pentosidine as a potential biological marker for AF in an AIS patient group.

Materials and methods. Sixty-three acute ischaemic hemispheric stroke patients were recruited and divided into two groups according to the presumed underlying mechanism: with or without atrial rhythm disorders. Ten healthy volunteers were a reference group for serum level of pentosidine. Carotid artery ultrasound was performed, and common carotid artery stiffness and intima-media thickness were measured. Serum levels of pentosidine and selected routine biochemical risk factors for atherosclerosis (cholesterol and its lipoprotein fractions, homocysteine) were examined.

Results. A higher serum level of pentosidine was observed in patients without atrial fibrillation (1,509 ± 485.13pmol/ml); a statistically significant difference was observed compared to the reference group (1,041.52 ± 411.17pmol/ml; p = 0.01), but not the AF patients (1,438.19 ± 495.97pmol/ml; p = 0.59). No significant difference in the non-AF group compared to the AF group for carotid intima-media thickness (IMT)/stiffness and pentosidine serum level was recorded.

Conclusions and clinical implications. A higher serum level of pentosidine was observed in AIS patients without atrial fibrillation compared to the healthy volunteers. According to the results of the present study, no difference between these patients in the selected risk factors of atherosclerosis were observed. Further studies are needed to identify a reliable marker of AF that would bring added value to the standard diagnostic workup after acute ischaemic stroke.

Abstract

Atrial fibrillation (AF) and atherosclerotic disease are independent risk factors for acute ischaemic stroke (AIS). The optimal biological marker which could allow differentiation between AF and non-AF AIS patients is still not available.

Aim of the study. Aim of the present study was to investigate the role of pentosidine as a potential biological marker for AF in an AIS patient group.

Materials and methods. Sixty-three acute ischaemic hemispheric stroke patients were recruited and divided into two groups according to the presumed underlying mechanism: with or without atrial rhythm disorders. Ten healthy volunteers were a reference group for serum level of pentosidine. Carotid artery ultrasound was performed, and common carotid artery stiffness and intima-media thickness were measured. Serum levels of pentosidine and selected routine biochemical risk factors for atherosclerosis (cholesterol and its lipoprotein fractions, homocysteine) were examined.

Results. A higher serum level of pentosidine was observed in patients without atrial fibrillation (1,509 ± 485.13pmol/ml); a statistically significant difference was observed compared to the reference group (1,041.52 ± 411.17pmol/ml; p = 0.01), but not the AF patients (1,438.19 ± 495.97pmol/ml; p = 0.59). No significant difference in the non-AF group compared to the AF group for carotid intima-media thickness (IMT)/stiffness and pentosidine serum level was recorded.

Conclusions and clinical implications. A higher serum level of pentosidine was observed in AIS patients without atrial fibrillation compared to the healthy volunteers. According to the results of the present study, no difference between these patients in the selected risk factors of atherosclerosis were observed. Further studies are needed to identify a reliable marker of AF that would bring added value to the standard diagnostic workup after acute ischaemic stroke.

Get Citation

Keywords

acute ischaemic stroke, atrial fibrillation, pentosidine, carotid ultrasound

About this article
Title

Pentosidine, advanced glycation end product, in acute ischaemic stroke patients with and without atrial rhythm disturbances

Journal

Neurologia i Neurochirurgia Polska

Issue

Vol 54, No 4 (2020)

Pages

323-328

Published online

2020-06-08

DOI

10.5603/PJNNS.a2020.0042

Pubmed

32510570

Bibliographic record

Neurol Neurochir Pol 2020;54(4):323-328.

Keywords

acute ischaemic stroke
atrial fibrillation
pentosidine
carotid ultrasound

Authors

Marta Leńska-Mieciek
Grażyna Korczak-Kowalska
Katarzyna Bocian
Urszula Fiszer

References (28)
  1. Deb P, Sharma S, Hassan KM. Pathophysiologic mechanisms of acute ischemic stroke: An overview with emphasis on therapeutic significance beyond thrombolysis. Pathophysiology. 2010; 17(3): 197–218.
  2. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991; 22(8): 983–988.
  3. Falk E. Pathogenesis of Atherosclerosis. Journal of the American College of Cardiology. 2006; 47(8): C7–C12.
  4. Szegedi I, Szapáry L, Csécsei P, et al. Potential Biological Markers of Atrial Fibrillation: A Chance to Prevent Cryptogenic Stroke. Biomed Res Int. 2017; 2017: 8153024.
  5. Ardhianto P, Yuniadi Y. Biomarkers of Atrial Fibrillation: Which One Is a True Marker? Cardiol Res Pract. 2019; 2019: 8302326.
  6. Bonomini F, Tengattini S, Fabiano A, et al. Atherosclerosis and oxidative stress. Histol Histopathol. 2008; 23(3): 381–390.
  7. Cowdry EV. Arteriosclerosis: A survey of problem. New York: MacMillan; 1933 [Introduction.
  8. Crowther MA. Pathogenesis of atherosclerosis. Hematology Am Soc Hematol Educ Program. 2005: 436–441.
  9. O'Leary DH, Bots ML. Imaging of atherosclerosis: carotid intima-media thickness. Eur Heart J. 2010; 31(14): 1682–1689.
  10. Stein JH, Korcarz CE, Hurst RT, et al. American Society of Echocardiography Carotid Intima-Media Thickness Task Force. Use of carotid ultrasound to identify subclinical vascular disease and evaluate cardiovascular disease risk: a consensus statement from the American Society of Echocardiography Carotid Intima-Media Thickness Task Force. Endorsed by the Society for Vascular Medicine. J Am Soc Echocardiogr. 2008; 21(2): 93–111; quiz 189.
  11. Bruno RM, Bianchini E, Faita F, et al. Intima media thickness, pulse wave velocity, and flow mediated dilation. Cardiovasc Ultrasound. 2014; 12: 34.
  12. Li H, Horke S, Förstermann U. Vascular oxidative stress, nitric oxide and atherosclerosis. Atherosclerosis. 2014; 237(1): 208–219.
  13. Yamagishi Si, Maeda S, Matsui T, et al. Role of advanced glycation end products (AGEs) and oxidative stress in vascular complications in diabetes. Biochim Biophys Acta. 2012; 1820(5): 663–671.
  14. Goldin A, Beckman JA, Schmidt AM, et al. Advanced glycation end products: sparking the development of diabetic vascular injury. Circulation. 2006; 114(6): 597–605.
  15. Cecelja M, Chowienczyk P. Role of arterial stiffness in cardiovascular disease. JRSM Cardiovasc Dis. 2012; 1(4).
  16. Kubozono T, Ohishi M. Prognostic Significance of Regional Arterial Stiffness for Stroke in Hypertension. Pulse (Basel). 2015; 3(2): 98–105.
  17. Ikeda T, Maruyama K, Ito N, et al. Serum pentosidine, an advanced glycation end product, indicates poor outcomes after acute ischemic stroke. J Stroke Cerebrovasc Dis. 2012; 21(5): 386–390.
  18. Ikeda T, Maruyama K, Ito N, et al. High serum pentosidine in branch atheromatous disease among small vessels occlusion. J Neurosurg Sci. 2019; 63(4): 388–393.
  19. Sánchez E, Betriu À, Yeramian A, et al. ILERVAS project, ILERVAS Project:. Skin Autofluorescence Measurement in Subclinical Atheromatous Disease: Results from the ILERVAS Project. J Atheroscler Thromb. 2019; 26(10): 879–889.
  20. Bekwelem W, Jensen PN, Norby FL, et al. Carotid Atherosclerosis and Stroke in Atrial Fibrillation: The Atherosclerosis Risk in Communities Study. Stroke. 2016; 47(6): 1643–1646.
  21. Gori N, Anania G, Stefani L, et al. Carotid Intima-Media Thickness in Master Athletes. Asian J Sports Med. 2015; 6(2): e22587.
  22. Chen Y, Xiong H, Wu D, et al. Relationship of short-term blood pressure variability with carotid intima-media thickness in hypertensive patients. Biomed Eng Online. 2015; 14: 71.
  23. Schiel R, Beltschikow W, Radón S, et al. Increased carotid intima-media thickness and associations with cardiovascular risk factors in obese and overweight children and adolescents. Eur J Med Res. 2007; 12(10): 503–508.
  24. Kawai T, Ohishi M, Takeya Y, et al. Carotid plaque score and intima media thickness as predictors of stroke and mortality in hypertensive patients. Hypertens Res. 2013; 36(10): 902–909.
  25. Chen LY, Leening MJG, Norby FL, et al. Carotid Intima-Media Thickness and Arterial Stiffness and the Risk of Atrial Fibrillation: The Atherosclerosis Risk in Communities (ARIC) Study, Multi-Ethnic Study of Atherosclerosis (MESA), and the Rotterdam Study. J Am Heart Assoc. 2016; 5(5).
  26. Gladstone DJ, Dorian P, Spring M, et al. EMBRACE Steering Committee and Investigators, EMBRACE Investigators and Coordinators. Atrial fibrillation in patients with cryptogenic stroke. N Engl J Med. 2014; 370(26): 2467–2477.
  27. Lumikari TJ, Putaala J, Kerola A, et al. Continuous 4-week ECG monitoring with adhesive electrodes reveals AF in patients with recent embolic stroke of undetermined source. Ann Noninvasive Electrocardiol. 2019; 24(5): e12649.
  28. Farkowski MM, Karliński MA, Kaźmierczak J, et al. Statement by a Working Group conceived by the Polish National Consultants in Cardiology and Neurology addressing the use of implantable cardiac monitors in patients after ischaemic embolic stroke of undetermined source. Neurol Neurochir Pol. 2019; 53(3): 181–189.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: viamedica@viamedica.pl